Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H23NO4 |
| Molecular Weight | 329.3902 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]1CC[C@@]2(O)[C@H]3CC4=CC=C(O)C5=C4[C@@]2(CCN3CC=C)[C@H]1O5
InChI
InChIKey=HMWHERQFMBEHNG-AQQQZIQISA-N
InChI=1S/C19H23NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,13-14,17,21-23H,1,5-10H2/t13-,14+,17-,18-,19+/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/11413242Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19061911 | https://www.ncbi.nlm.nih.gov/pubmed/15956992
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11413242
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19061911 | https://www.ncbi.nlm.nih.gov/pubmed/15956992
6-alpha-Naloxol is active metabolite of naloxone. 6-alpha-Naloxol was shown to be neutral antagonist at the mu receptor in vitro, with no affect on cAMP levels or GTPitalic gammaS binding, regardless of morphine pretreatment. It elicits withdrawal behaviour and conditioned place aversion in morphine pretreated rodents.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19061911 | https://www.ncbi.nlm.nih.gov/pubmed/15956992
Curator's Comment: 6-alpha-Naloxol is CNS active in animals. No human data available.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11413242 |
0.63 nM [Ki] | ||
Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11413242 |
2.1 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Relative potency of the opioid antagonists naloxone and 6-alpha-naloxol to precipitate withdrawal from acute morphine dependence varies with time post-antagonist. | 2009-03 |
|
| Constitutively active micro opioid receptors mediate the enhanced conditioned aversive effect of naloxone in morphine-dependent mice. | 2006-01 |
|
| Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. | 2001-06 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15956992
rats: 0.05–100 mg/kg, s.c.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID20942579
Created by
admin on Mon Mar 31 23:27:48 GMT 2025 , Edited by admin on Mon Mar 31 23:27:48 GMT 2025
|
PRIMARY | |||
|
5492271
Created by
admin on Mon Mar 31 23:27:48 GMT 2025 , Edited by admin on Mon Mar 31 23:27:48 GMT 2025
|
PRIMARY | |||
|
Naloxol
Created by
admin on Mon Mar 31 23:27:48 GMT 2025 , Edited by admin on Mon Mar 31 23:27:48 GMT 2025
|
PRIMARY | |||
|
m11769
Created by
admin on Mon Mar 31 23:27:48 GMT 2025 , Edited by admin on Mon Mar 31 23:27:48 GMT 2025
|
PRIMARY | |||
|
300000013056
Created by
admin on Mon Mar 31 23:27:48 GMT 2025 , Edited by admin on Mon Mar 31 23:27:48 GMT 2025
|
PRIMARY | |||
|
20410-95-1
Created by
admin on Mon Mar 31 23:27:48 GMT 2025 , Edited by admin on Mon Mar 31 23:27:48 GMT 2025
|
PRIMARY | |||
|
FLW43Q2H9L
Created by
admin on Mon Mar 31 23:27:48 GMT 2025 , Edited by admin on Mon Mar 31 23:27:48 GMT 2025
|
PRIMARY |
PARENT (METABOLITE LESS ACTIVE)
SUBSTANCE RECORD